In vitro antimalarial susceptibility and molecular markers of drug resistance in Franceville, Gabon

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Zatra, Rafika ^a   Lekana douki, Jean B ^a,b   Lekoulou, Faustin ^a   Bisvigou, Ulrick ^a,b   Ngoungou, Edgard B ^b   Ndouo, Fousseyni S T ^a  

^a CENTRE INTERNATIONAL DE RECHERCHES MÉDICALES DE FRANCEVILLE   (Gabon)

^b UNIVERSITÉ DES SCIENCES DE LA SANTÉ   (Gabon)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; DEETHYLAMODIAQUINE; DIHYDROARTEMISININ; MEFLOQUINE;

ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; CHI SQUARE TEST; CODON; COLORIMETRY; COMPUTER PROGRAM; CROSS-SECTIONAL STUDY; GABON; GENE; GENETIC POLYMORPHISM; HAPLOTYPE; HEMATOLOGICAL PARAMETERS; IC 50; IN VITRO STUDY; NONHUMAN; PFATPASE6 GENE; PFCRT GENE; PFMDR1 GENE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ANIMALS; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE; FEMALE; GABON; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 84868685072     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-307     Document Type: Article

References (53)

1. WHO World Malaria Report 2010 2010, 32. Geneva: World Health Organization, WHO.
2. Wang P, Read M, Sims PF, Hyde JE. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Mol Microbiol 1997, 23(5):979-986. 10.1046/j.1365-2958.1997.2821646.x, 9076734.
3. Basco LK, Tahar R, Ringwald P. Molecular basis of in vivo resistance to sulfadoxine-pyrimethamine in African adult patients infected with Plasmodium falciparum malaria parasites. Antimicrob Agents Chemother 1998, 42(7):1811-1814. 105688, 9661026.
4. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 2001, 344(4):257-263. 10.1056/NEJM200101253440403, 11172152.
5. Basco LK, Ndounga M, Ngane VF, Soula G. Molecular epidemiology of malaria in Cameroon. XIV. Plasmodium falciparum chloroquine resistance transporter (PFCRT) gene sequences of isolates before and after chloroquine treatment. Am J Trop Med Hyg 2002, 67(4):392-395.
6. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sidhu AB, Naude B, Deitsch KW, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 2000, 6(4):861-871. 10.1016/S1097-2765(05)00077-8, 2944663, 11090624.
7. Foote SJ, Kyle DE, Martin RK, Oduola AM, Forsyth K, Kemp DJ, Cowman AF. Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature 1990, 345(6272):255-258. 10.1038/345255a0, 2185424.
8. Pickard AL, Wongsrichanalai C, Purfield A, Kamwendo D, Emery K, Zalewski C, Kawamoto F, Miller RS, Meshnick SR. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob Agents Chemother 2003, 47(8):2418-2423. 10.1128/AAC.47.8.2418-2423.2003, 166057, 12878499.
9. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 2000, 403(6772):906-909. 10.1038/35002615, 10706290.
10. Peel SA, Bright P, Yount B, Handy J, Baric RS. A strong association between mefloquine and halofantrine resistance and amplification, overexpression, and mutation in the P-glycoprotein gene homolog (pfmdr) of Plasmodium falciparum in vitro. Am J Trop Med Hyg 1994, 51(5):648-658.
11. Cowman AF, Galatis D, Thompson JK. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc Natl Acad Sci U S A 1994, 91(3):1143-1147. 10.1073/pnas.91.3.1143, 521470, 8302844.
12. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 2007, 77(6 Suppl):181-192.
13. Alam MT, de Souza DK, Vinayak S, Griffing SM, Poe AC, Duah NO, Ghansah A, Asamoa K, Slutsker L, Wilson MD, et al. Selective sweeps and genetic lineages of Plasmodium falciparum drug -resistant alleles in Ghana. J Infect Dis 2011, 203(2):220-227. 10.1093/infdis/jiq038, 3071065, 21288822.
14. Some AF, Sere YY, Dokomajilar C, Zongo I, Rouamba N, Greenhouse B, Ouedraogo JB, Rosenthal PJ. Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother 2010, 54(5):1949-1954. 10.1128/AAC.01413-09, 2863637, 20231394.
15. Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Bjorkman A, Gil JP. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis 2005, 191(6):1014-1017. 10.1086/427997, 15717281.
16. Aubouy A, Bakary M, Keundjian A, Mbomat B, Makita JR, Migot-Nabias F, Cot M, Le Bras J, Deloron P. Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children. Antimicrob Agents Chemother 2003, 47(1):231-237. 10.1128/AAC.47.1.231-237.2003, 148969, 12499196.
17. Nsimba B, Guiyedi V, Mabika-Mamfoumbi M, Mourou-Mbina JR, Ngoungou E, Bouyou-Akotet M, Loembet R, Durand R, Le Bras J, Kombila M. Sulphadoxine/pyrimethamine versus amodiaquine for treating uncomplicated childhood malaria in Gabon: a randomized trial to guide national policy. Malar J 2008, 7:31. 10.1186/1475-2875-7-31, 2276509, 18267042.
18. Ndong JM, Atteke C, Aubouy A, Bakary M, Lebibi J, Deloron P. In vitro activity of chloroquine, quinine, mefloquine and halofantrine against Gabonese isolates of Plasmodium falciparum. Trop Med Int Health 2003, 8(1):25-29. 10.1046/j.1365-3156.2003.00967.x, 12535246.
19. Ramharter M, Wernsdorfer WH, Kremsner PG. In vitro activity of quinolines against Plasmodium falciparum in Gabon. Acta Trop 2004, 90(1):55-60. 10.1016/j.actatropica.2003.11.001, 14739023.
20. Bouyou-Akotet MK, Mawili-Mboumba DP, Kendjo E, Mabika-Mamfoumbi M, Ngoungou EB, Dzeing-Ella A, Pemba-Mihindou M, Ibinga E, Efame-Eya E, Planche T, et al. Evidence of decline of malaria in the general hospital of Libreville, Gabon from 2000 to 2008. Malar J 2009, 8(1):300. 10.1186/1475-2875-8-300, 2806380, 20017905.
21. Lekana-Douki JB, Boutamba SD, Zatra R, Edou SE, Ekomy H, Bisvigou U, Toure-Ndouo FS. Increased prevalence of the Plasmodium falciparum Pfmdr1 86N genotype among field isolates from Franceville, Gabon after replacement of chloroquine by artemether-lumefantrine and artesunate-mefloquine. Infect Genet Evol 2011, 11(2):512-517. 10.1016/j.meegid.2011.01.003, 21251998.
22. Lim P, Alker AP, Khim N, Shah NK, Incardona S, Doung S, Yi P, Bouth DM, Bouchier C, Puijalon OM, et al. Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar J 2009, 8:11. 10.1186/1475-2875-8-11, 2627910, 19138391.
23. Pascual A, Basco LK, Baret E, Amalvict R, Travers D, Rogier C, Pradines B. Use of the atmospheric generators for capnophilic bacteria Genbag-CO2 for the evaluation of in vitro Plasmodium falciparum susceptibility to standard anti-malarial drugs. Malar J 2011, 10(1):8. 10.1186/1475-2875-10-8, 3031278, 21235757.
24. Okombo J, Kiara SM, Rono J, Mwai L, Pole L, Ohuma E, Borrmann S, Ochola LI, Nzila A. In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya. Antimicrob Agents Chemother 2010, 54(8):3302-3307. 10.1128/AAC.00325-10, 2916339, 20516285.
25. Planche T, Krishna S, Kombila M, Engel K, Faucher JF, Ngou-Milama E, Kremsner PG. Comparison of methods for the rapid laboratory assessment of children with malaria. Am J Trop Med Hyg 2001, 65(5):599-602.
26. Douki JB, Sterkers Y, Lepolard C, Traore B, Costa FT, Scherf A, Gysin J. Adhesion of normal and Plasmodium falciparum ring-infected erythrocytes to endothelial cells and the placenta involves the rhoptry-derived ring surface protein-2. Blood 2003, 101(12):5025-5032. 10.1182/blood-2002-12-3710, 12609837.
27. Trager W, Jensen JB. Human malaria parasites in continuous culture. Science 1976, 193(4254):673-675. 10.1126/science.781840, 781840.
28. Druilhe P, Moreno A, Blanc C, Brasseur PH, Jacquier P. A colorimetric in vitro drug sensitivity assay for Plasmodium falciparum based on a highly sensitive double-site lactate dehydrogenase antigen-capture enzyme-linked immunosorbent assay. Am J Trop Med Hyg 2001, 64(5-6):233-241.
29. Kaddouri H, Nakache S, Houze S, Mentre F, Le Bras J. Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from africa by using a Plasmodium lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration. Antimicrob Agents Chemother 2006, 50(10):3343-3349. 10.1128/AAC.00367-06, 1610081, 17005815.
30. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol Biochem Parasitol 2000, 108(1):13-23. 10.1016/S0166-6851(00)00201-2, 10802315.
31. Happi CT, Gbotosho GO, Folarin OA, Sowunmi A, Hudson T, O'Neil M, Milhous W, Wirth DF, Oduola AM. Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria. Antimicrob Agents Chemother 2009, 53(3):888-895. 10.1128/AAC.00968-08, 2650543, 19075074.
32. Pradines B, Fusai T, Daries W, Laloge V, Rogier C, Millet P, Panconi E, Kombila M, Parzy D. Ferrocene-chloroquine analogues as antimalarial agents: in vitro activity of ferrochloroquine against 103 Gabonese isolates of Plasmodium falciparum. J Antimicrob Chemother 2001, 48(2):179-184. 10.1093/jac/48.2.179, 11481286.
33. Aubouy A, Mayombo J, Keundjian A, Bakary M, Le Bras J, Deloron P. Short report: lack of prediction of amodiaquine efficacy in treating Plasmodium falciparum malaria by in vitro tests. Am J Trop Med Hyg 2004, 71(3):294-296.
34. Nsobya SL, Kiggundu M, Nanyunja S, Joloba M, Greenhouse B, Rosenthal PJ. In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob Agents Chemother 2010, 54(3):1200-1206. 10.1128/AAC.01412-09, 2825959, 20065051.
35. Pradines B, Mabika Mamfoumbi M, Parzy D, Owono Medang M, Lebeau C, Mourou Mbina JR, Doury JC, Kombila M. In vitro susceptibility of Gabonese wild isolates of Plasmodium falciparum to artemether, and comparison with chloroquine, quinine, halofantrine and amodiaquine. Parasitology 1998, 117(Pt 6):541-545.
36. Philipps J, Radloff PD, Wernsdorfer W, Kremsner PG. Follow-up of the susceptibility of Plasmodium falciparum to antimalarials in Gabon. Am J Trop Med Hyg 1998, 58(5):612-618.
37. Peters W, Howells RE, Portus J, Robinson BL, Thomas S, Warhurst DC. The chemotherapy of rodent malaria, XXVII. Studies on mefloquine (WR 142,490). Ann Trop Med Parasitol 1977, 71(4):407-418.
38. Platel DF, Mangou F, Tribouley-Duret J. High-level chloroquine resistance of Plasmodium berghei is associated with multiple drug resistance and loss of reversal by calcium antagonists. Int J Parasitol 1998, 28(4):641-651. 10.1016/S0020-7519(98)00010-1, 9602389.
39. Dahlstrom S, Ferreira PE, Veiga MI, Sedighi N, Wiklund L, Martensson A, Farnert A, Sisowath C, Osorio L, Darban H, et al. Plasmodium falciparum multidrug resistance protein 1 and artemisinin-based combination therapy in Africa. J Infect Dis 2009, 200(9):1456-1464. 10.1086/606009, 19807279.
40. Dokomajilar C, Lankoande ZM, Dorsey G, Zongo I, Ouedraogo JB, Rosenthal PJ. Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso. Am J Trop Med Hyg 2006, 75(1):162-165.
41. Raman J, Mauff K, Muianga P, Mussa A, Maharaj R, Barnes KI. Five years of antimalarial resistance marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy roll out. PLoS One 2011, 6(10):e25992. 10.1371/journal.pone.0025992, 3195082, 22022487.
42. Mwai L, Kiara SM, Abdirahman A, Pole L, Rippert A, Diriye A, Bull P, Marsh K, Borrmann S, Nzila A. In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother 2009, 53(12):5069-5073. 10.1128/AAC.00638-09, 2786317, 19770282.
43. Grobusch MP, Adagu IS, Kremsner PG, Warhurst DC. Plasmodium falciparum: in vitro chloroquine susceptibility and allele-specific PCR detection of Pfmdr1 Asn86Tyr polymorphism in Lambarene, Gabon. Parasitology 1998, 116(Pt 3):211-217.
44. Dlamini SV, Beshir K, Sutherland CJ. Markers of anti-malarial drug resistance in Plasmodium falciparum isolates from Swaziland: identification of pfmdr1-86F in natural parasite isolates. Malar J 2010, 9:68. 10.1186/1475-2875-9-68, 2845184, 20199676.
45. Mungthin M, Khositnithikul R, Sitthichot N, Suwandittakul N, Wattanaveeradej V, Ward SA, Na-Bangchang K. Association between the pfmdr1 gene and in vitro artemether and lumefantrine sensitivity in Thai isolates of Plasmodium falciparum. Am J Trop Med Hyg 2010, 83(5):1005-1009. 10.4269/ajtmh.2010.10-0339, 2963959, 21036827.
46. Alifrangis M, Dalgaard MB, Lusingu JP, Vestergaard LS, Staalsoe T, Jensen AT, Enevold A, Ronn AM, Khalil IF, Warhurst DC, et al. Occurrence of the Southeast Asian/South American SVMNT haplotype of the chloroquine-resistance transporter gene in Plasmodium falciparum in Tanzania. J Infect Dis 2006, 193(12):1738-1741. 10.1086/504269, 16703518.
47. Gama BE, Pereira-Carvalho GA, Lutucuta Kosi FJ, de Oliveira NK A, Fortes F, Rosenthal PJ, Daniel-Ribeiro CT, De Fatima Ferreira-da-Cruz M. Plasmodium falciparum isolates from Angola show the StctVMNT haplotype in the pfcrt gene. Malar J 2010, 9:174. 10.1186/1475-2875-9-174, 2898790, 20565881.
48. Warhurst DC. Polymorphism in the Plasmodium falciparum chloroquine-resistance transporter protein links verapamil enhancement of chloroquine sensitivity with the clinical efficacy of amodiaquine. Malar J 2003, 2:31. 10.1186/1475-2875-2-31, 269985, 14599295.
49. Beshir K, Sutherland CJ, Merinopoulos I, Durrani N, Leslie T, Rowland M, Hallett RL. Amodiaquine resistance in Plasmodium falciparum malaria in Afghanistan is associated with the pfcrt SVMNT allele at codons 72 to 76. Antimicrob Agents Chemother 2010, 54(9):3714-3716. 10.1128/AAC.00358-10, 2934991, 20547800.
50. Muangnoicharoen S, Johnson DJ, Looareesuwan S, Krudsood S, Ward SA. Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro. Antimicrob Agents Chemother 2009, 53(4):1362-1366. 10.1128/AAC.01656-08, 2663099, 19188388.
51. Tahar R, Ringwald P, Basco LK. Molecular epidemiology of malaria in Cameroon. XXVIII. In vitro activity of dihydroartemisinin against clinical isolates of Plasmodium falciparum and sequence analysis of the P. falciparum ATPase 6 gene. Am J Trop Med Hyg 2009, 81(1):13-18.
52. Ibrahim ML, Khim N, Adam HH, Ariey F, Duchemin JB. Polymorphism of PfATPase in Niger: detection of three new point mutations. Malar J 2009, 8:28. 10.1186/1475-2875-8-28, 2661090, 19226462.
53. Dahlstrom S, Veiga MI, Ferreira P, Martensson A, Kaneko A, Andersson B, Bjorkman A, Gil JP. Diversity of the sarco/endoplasmic reticulum Ca(2+)-ATPase orthologue of Plasmodium falciparum (PfATP6). Infect Genet Evol 2008, 8(3):340-345. 10.1016/j.meegid.2008.02.002, 18359278.